Background Patients with asthma who have persistent symptoms despite treatment with
inhaled steroids and long-acting beta agonists are considered to have severe asthma …

Background: Patients with severe persistent asthma who are inadequately controlled
despite treatment according to current asthma management guidelines have a significant …

Introduction: Omalizumab is the first mAb to be introduced for the management of asthma. It
is also the first agent designed to block the effects of IgE in initiating the allergic cascade …

Background Asthma is a respiratory (airway) condition that affects an estimated 300 million
people worldwide and is associated with significant morbidity and mortality. Omalizumab is …

Omalizumab is a humanized murine monoclonal antibody directed toward a portion of the
IgE indicated in Europe for the treatment of severe persistent allergic asthma, inadequately …

Background: Although there are many studies presenting the efficacy of omalizumab in
severe asthma, the data about the optimal treatment duration are still debated. Objective: In …

Increased asthma severity is not only associated with enhanced recurrent hospitalization
and mortality but also with higher social costs. Several cases of asthma are atopic in nature …

Background: Omalizumab is a monoclonal, humanized antibody specific for the region of IgE
that binds to the high affinity IgE receptor on basophils and mast cells. Subcutaneous …

Background Patients with severe asthma are often inadequately controlled on existing anti‐
asthma therapy, constituting an unmet clinical need. Objective This randomized, double …

Immunoglobulin E (IgE) plays a critical role in the allergen-initiated inflammatory pathway
and thus serves as a viable therapeutic target in allergic or IgE-mediated diseases such as …